Anthem Biosciences IPO

Integrated Capabilities: It is the only Indian CRDMO among assessed peers with strong capabilities in both small molecules and biologics (large molecules). This allows it to offer comprehensive, end-to-end services from discovery to commercial manufacturing across the drug lifecycle.

Industry-Leading Financial Performance: Achieved the highest revenue growth (29.96%) from FY24 to FY25 among assessed Indian and global peers. In FY25, its EBITDA margin of 36.81% was the highest among Indian peers and the second highest globally.

Advanced Technology & Portfolio: Possesses expertise in advanced modalities like RNAi, ADC, peptides, and oligonucleotides, supported by manufacturing capabilities such as flow chemistry and biotransformation. Its specialty ingredients business, a complementary revenue stream, contributed 18.35% of revenue in FY25.

Strong Return Ratios: Anthem Biosciences delivered an impressive Return on Equity (ROE) of 20.82% and post-tax Return on Capital Employed (ROCE) of 26.88% in FY25—the highest among Indian peers like Divi’s, Syngene, and Sai Life Sciences, and one of the best globally. This reflects the company's efficient capital use and strong profitability.

Superior Fermentation Capacity: Operates the largest fermentation capacity (142 kL as of March 31, 2025) among assessed Indian CRDMOs. This capacity is projected to increase to 182 kL by the first half of FY26, being more than six times that of the second-largest assessed player.

Skilled Talent Pool: Led by a professional founding team with over 25 years of industry experience, it is supported by 1,015 scientific staff, including 35 PhDs and over 1,100 Masters-degree holders as of March 31, 2025. This deep expertise fuels innovation and operational efficiency.

Customer Concentration: Highly dependent on key customers; its top 5 and top 10 customers contributed 70.92% and 77.33% respectively of its revenue from operations in FY25. Losing any of these key customers or a significant revenue decrease could adversely impact its business and results of operations.

Single-Source Supplier Reliance: Increased dependency on a single-source overseas supplier in the PRC contributed to 48.41% of its FY25 raw material costs (up from 24.60% in FY24). Price increases or supply interruptions could significantly harm its business operations and financial condition.

Highly Fragmented Competition: Operates in a highly fragmented CRDMO market with over 1,000 to 1,500 global competitors as of March 2025. Facing significant competition from various players, including Syngene International and Lonza Group, could pressure its pricing and profitability.

Longer Cash Cycle Could Strain Operations: In FY25, Anthem’s Net Working Capital Days stood at 222, much higher than Syngene (34), Sai Life (109), and Divi’s (182), though slightly better than Cohance (252). Its Inventory Days were 135, also higher than Syngene (76) and Sai Life (81). This means Anthem takes more time to collect payments and manage inventory, which can lock up cash and slow down business expansion or daily operations.

Workforce Dependency: The company heavily relies on its 2,062 employees, including 1,015 scientific staff and 35 PhDs. Inability to attract or retain this skilled workforce due to intense competition may cause knowledge loss and adversely impact its business performance.